Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label U.S. Food and Drug Administration. Show all posts
Showing posts with label U.S. Food and Drug Administration. Show all posts
Monday, August 3, 2026

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

›
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies desi...
Saturday, June 6, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

›
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) ...
Friday, June 5, 2026

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

›
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), t...
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.